EFFICACY AND SAFETY OF CLADRIBINE: SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION IN HAIRY CELL LEUKEMIA PATIENTS

Autor: Ola, Khorshid, Alfred Elias, Namour, Mosaad M, El-Gammal, Tarek Yakout, Mahmoud, Catherine, Fortpied, Raafat, Abdel-Malek, Safaa, Ramadan

Publikováno v: Mediterranean Journal of Hematology and Infectious Diseases, Vol 7, Iss 1, Pp e2015058-e2015058 (2015)
Mediterranean Journal of Hematology and Infectious Diseases

Cladribine induces durable complete remission (CR) in approximately 85% of hairy cell leukemia (HCL) patients. In Egypt, cladribine is mainly used as IV continuous infusion at a dose of 0.1 mg/kg/day for 7 days and as SC bolus injection at a dose of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb2013a7606744264b05e51e658861b6
https://doi.org/10.4084/mjhid.2015.058